David Miklos
Hematology · Stanford, CANPI 1982751053
Payments from drug & device makers
Across 420 payments — averaging $24,985 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Gilead$7.8M
- Adaptive Biotechnologies Corporation$2.1M
- Regeneron$291K
- Pharmacyclics LLC, An Abbvie Company$163K
- Novartis$71K
- Bristol Myers Squibb$30K
- plus $21K from 16 others
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Gilead(2 entities) | 254 | $7,806,681 |
| Adaptive Biotechnologies Corporation | 53 | $2,110,355 |
| Regeneron | 16 | $291,227 |
| Pharmacyclics LLC, An Abbvie Company | 47 | $162,614 |
| Novartis | 16 | $71,029 |
| Bristol Myers Squibb | 9 | $30,303 |
| EUSA Pharma (US) LLC | 3 | $6,205 |
| E.r. Squibb & Sons, L.L.C. | 2 | $5,253 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $2,640 |
| Janssen Global Services, LLC | 1 | $2,480 |
| Novartis Pharma AG | 2 | $1,811 |
| Janssen Scientific Affairs, LLC | 1 | $1,240 |
| Eli Lilly | 1 | $1,000 |
| Sobi, Inc | 2 | $190 |
| Stryker | 4 | $182 |
| Beone Medicines USA, Inc. | 2 | $181 |
| AstraZeneca | 1 | $96 |
| Johnson & Johnson | 1 | $79 |
| Iovance Biotherapeutics, Inc. | 1 | $48 |
| CSL Behring | 1 | $25 |
| Genetix Biotherapeutics Inc | 1 | $23 |
| Amgen | 1 | $19 |
How this compares
$10,493,681 in reported general payments places this provider in the 90th percentile of 178 hematology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other hematology in Stanford
- Tait ShanafeltStanford$441.4M
- Wei DingStanford$3.7M
- Deepu MadduriStanford$3.6M
- Saurabh DahiyaStanford$3.2M
- Michaela LiedtkeStanford$3.1M
- Surbhi SidanaStanford$3M
- Everett MeyerStanford$2.2M
- Sally AraiStanford$2.2M
- Lori MufflyStanford$2.1M
- William ShomaliStanford$2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.